Latest News of APLS
Should You Hold Apellis Pharmaceuticals (APLS)?
By Yahoo! Finance |
1 month ago
PGIM Jennison Health Sciences Fund's Q2 2024 investor letter discusses its performance, highlighting Apellis Pharmaceuticals, Inc. (APLS) as a key stock. Despite a decline, the fund sees potential in ...
Apellis Pharmaceuticals, Inc. (APLS): Among Hedge Funds' Top Biotech Stock Picks
By Yahoo! Finance |
1 month ago
Insider Monkey analyzed the top biotech hedge funds and their stock picks, focusing on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS). Biotech stocks are risky due to clinical trials' impact on stock ret...
Apellis Pharmaceuticals, Inc. (APLS): Among the Best Mid-Cap Healthcare Stocks To Buy Now
By Yahoo! Finance |
2 months ago
Apellis Pharmaceuticals is a biopharmaceutical company focusing on rare diseases. Its drug SYFOVRE shows strong demand, with projected growth. With 38 hedge funds holding stakes, APLS ranks 10th in th...
-
When Will Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Breakeven?
By Yahoo! Finance | 3 months agoApellis Pharmaceuticals is a biopharmaceutical company on the brink of profitability. Analysts predict it will break even in 2024, with a projected growth rate of 63%....
-
Investors might be losing patience for Apellis Pharmaceuticals' (NASDAQ:APLS) increasing losses, as stock sheds 6.3% over the past week
By Yahoo! Finance | 4 months agoDespite recent stock price decline, Apellis Pharmaceuticals has shown strong revenue growth of 48% per year over the last 5 years. While short-term shareholders faced losses, long-term investors gaine...